Мультимодальная терапия остеоартрита. III Всероссийская научно-практическая конференция «Скелетно-мышечная боль при ревматических заболеваниях». Обзор симпозиума 22 сентября 2023 г., Москва, Россия

1. Chaney S, Vergara R, Qiryaqoz Z, et al. The Involvement of Neutrophils in the Pathophysiology and Treatment of Osteoarthritis. Biomedicines. 2022;10(7):1604. DOI:10.3390/biomedicines10071604
2. Галушко Е.А., Большакова Т.Ю., Виноградова И.Б., и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практическая ревматология. 2009;47(1):11-7 [Galushko EA, Bolshakova TY, Vinogradova IB, et al. Structure of rheumatic diseases among adult population of Russia according to data of an epidemiological study (preliminary results). Rheumatology Science and Practice. 2009;47(1):11-7 (in Russian)]. DOI:10.14412/1995-4484-2009-136
3. Berenbaum F. Deep phenotyping of osteoarthritis: a step forward. Ann Rheum Dis. 2019;78(1):3-5. DOI:10.1136/annrheumdis-2018-213864
4. Лила А.М., Алексеева Л.И., Телышев К.А. Современные подходы к фенотипированию остеоартрита. Современная ревматология. 2019;13(2):4-8 [Lila AM, Alekseeva LI, Telyshev KA. Current approaches to osteoarthritis phenotyping. Modern Rheumatology Journal. 2019;13(2):4-8 (in Russian)].
5. Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018;320(24):2564-79. DOI:10.1001/jama.2018.19319
6. Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008;16(2):254-60. DOI:10.1016/j.joca.2007.06.011
7. Rovati LC, Girolami F, D'Amato M, Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016;45(Suppl. 4):S34-41. DOI:10.1016/j.semarthrit.2015.10.009
8. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254-66. DOI:10.1002/stem.1634
9. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol. 2013;9(10):584-94. DOI:10.1038/nrrheum.2013.109
10. Алексеева Л.И. Новые представления о патогенезе остеоартрита, роль метаболических нарушений. Ожирение и метаболизм. 2019;16(2):75-82 [Alekseeva LI. New ideas about the pathogenesis of osteoarthritis, the role of metabolic disorders. Obesity and Metabolism. 2019;16(2):75-82 (in Russian)]. DOI:10.14341/omet10274
11. Dagnino APA, Campos MM. Chronic Pain in the Elderly: Mechanisms and Perspectives. Front Hum Neurosci. 2022;16:736688. DOI:10.3389/fnhum.2022.736688
12. Leyland KM, Gates LS, Sanchez-Santos MT, et al; PCCOA Steering Committee. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res. 2021;33(3):529-45. DOI:10.1007/s40520-020-01762-2
13. Wang Y, Teichtahl AJ, Abram F, et al. Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Res Ther. 2018;20(1):250. DOI:10.1186/s13075-018-1751-4
14. Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797-807. DOI:10.1136/annrheumdis-2017-212662
15. Lim YZ, Wong J, Hussain SM, et al. Recommendations for weight management in osteoarthritis: A systematic review of clinical practice guidelines. Osteoarthr Cartil Open. 2022;4(4):100298. DOI:10.1016/j.ocarto.2022.100298
16. Stoll V, Jost JM, Jack A, et al. Non-steroidal Anti-inflammatory Drugs and Osteopathic Manipulative Treatment for Pain Management in Patients With Osteoarthritis: A Literature Review. Cureus. 2023;15(8):e44168. DOI:10.7759/cureus.44168
17. Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50. DOI:10.1016/j.semarthrit.2019.04.008
18. Гонартроз. Клинические рекомендации Минздрава РФ. 2021 [Gonartroz. Klinicheskie rekomendatsii Minzdrava RF. 2021 (in Russian)].
19. Коксартроз. Клинические рекомендации Минздрава РФ. 2021 [Koksartroz. Klinicheskie rekomendatsii Minzdrava RF. 2021 (in Russian)].
20. Uitterlinden EJ, Koevoet JL, Verkoelen CF, et al. Glucosamine increases hyaluronic acid production in human osteoarthritic synovium explants. BMC Musculoskelet Disord. 2008;9:120. DOI:10.1186/1471-2474-9-120
21. Veronese N, Demurtas J, Smith L, et al; on behalf on the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975927. DOI:10.1177/1759720X20975927
22. Алексеева Л.И., Шарапова Е.П., Лила А.М. Остеоартрит суставов кистей: распространенность, факторы риска, фенотипы, диагностика, лечение. Современная ревматология. 2022;16(6):98-105 [Alekseeva LI, Sharapova EP, Lila AM. Osteoarthritis of hand joints: prevalence, risk factors, phenotypes, diagnosis, treatment. Modern Rheumatology Journal. 2022;16(6):98-105 (in Russian)]. DOI:10.14412/1996-7012-2022-6-98-105
23. Tenti S, Giordano N, Mondanelli N, et al. A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone. Aging Clin Exp Res. 2020;32(6):1161-72. DOI:10.1007/s40520-019-01305-4
24. Reichelt A, Förster KK, Fischer M, et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. Arzneimittelforschung. 1994;44(1):75-80. PMID: 8135881
25. Honvo G, Reginster JY, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl. 1):65-99. DOI:10.1007/s40266-019-00662-z
26. Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P, et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis. 2016;245: 82-7. DOI:10.1016/j.atherosclerosis.2015.12.016
27. Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother. 2006;40(4): 694-8. DOI:10.1345/aph.1E658
28. Al-Kurdi ZI, Chowdhry BZ, Leharne SA, et al. Influence of glucosamine on the bioactivity of insulin delivered subcutaneously and in an oral nanodelivery system. Drug Des Devel Ther. 2015;9:6167-76. DOI:10.2147/DDDT.S91974
29. Cheng BR, Chen JQ, Zhang XW, et al. Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis. PLoS One. 2021;16(12):e0261239. DOI:10.1371/journal.pone.0261239
30. Nakata K, Hanai T, Take Y, et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2018;26(10):1263-73. DOI:10.1016/j.joca.2018.05.021
31. Taqi A, Gran S, Knaggs RD. Analgesic utilization in people with knee osteoarthritis: A population-based study using primary care data. Pain Pract. 2023;23(5):523-34. DOI:10.1111/papr.13212
32. Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(Suppl. 4):S22-7. DOI:10.1016/j.semarthrit.2015.11.009
33. Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-90.
DOI:10.1038/s41574-018-0059-4
34. Arendt Nielsen L, Schepman P, Hygge Blakeman K, et al. Prescription patterns and predictors of unmet pain relief in patients with difficult-to-treat osteoarthritis in the Nordics: analyses from the BISCUITS study. Scand J Pain. 2022;23(1):149-60. DOI:10.1515/sjpain-2021-0211
35. Swain S, Sarmanova A, Coupland C, et al. Comorbidities in Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken). 2020;72(7):991-1000. DOI:10.1002/acr.24008
36. Ryan A, Wallace E, O'Hara P, Smith SM. Multimorbidity and functional decline in community-dwelling adults: a systematic review. Health Qual Life Outcomes. 2015;13:168. DOI:10.1186/s12955-015-0355-9
37. Fortin M, Lapointe L, Hudon C, et al. Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes. 2004;2:51. DOI:10.1186/1477-7525-2-51
38. Каратеев А.Е., Алексеева Л.И., Цурган А.В., Гонтаренко Н.В. Терапия острой/подострой скелетно-мышечной боли: результаты наблюдательного исследования АЛИСА (Анальгетическое Лечение с Использованием Системного Алгоритма). Терапевтический архив. 2017;89(12):175-84 [Karateev AE, Alekseeva LI, Tsurgan AV, Gontarenko NV. Therapy for acute/subacute musculoskeletal pain: results of the ATUSA (Analgesic Treatment Using a Systemic Algorithm) observational study. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(12):175-84 (in Russian)]. DOI:10.17116/terarkh20178912175-184
39. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12(5):570-6. DOI:10.1097/00001648-200109000-00018
40. Roberto G, Simonetti M, Piccinni C, et al. Risk of Acute Cerebrovascular and Cardiovascular Events Among Users of Acetaminophen or an Acetaminophen-Codeine Combination in a Cohort of Patients with Osteoarthritis: A Nested Case-Control Study. Pharmacotherapy. 2015;35(10):899-909. DOI:10.1002/phar.1646
41. Pontes C, Marsal JR, Elorza JM, et al. Analgesic Use and Risk for Acute Coronary Events in Patients With Osteoarthritis: A Population-based, Nested Case-control Study. Clin Ther. 2018;40(2):270-83. DOI:10.1016/j.clinthera.2017.12.011
42. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968-76. DOI:10.1001/archinternmed.2010.391
43. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., и др.; Ассоциация ревматологов России, Российское общество по изучению боли, Российская гастроэнтерологическая ассоциация, Российское научное медицинское общество терапевтов, Ассоциация травматологов-ортопедов России, Российская ассоциация паллиативной медицины. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(прил. 1):1-29 [Karateev AE, Nasonov EL, Ivashkin VT, et al; Association of Rheumatologists of Russia, Russian Society for the Study of Pain, Russian Gastroenterology Association, Russian Scientific Medical Society of Therapists, Association of Traumatologists and Orthopedists of Russia, Russian Association of Palliative Medicine. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56(прил. 1):1-29 (in Russian)]. DOI:10.14412/1995-4484-2018-1-29
44. Каратеев А.Е. Целекоксиб, эторикоксиб, мелоксикам и нимесулид: сравнение достоинств и недостатков. Современная ревматология. 2011;(2):9-19 [Karateev AE. Celecoxib, etoricoxib, meloxicam and nimesulide: comparison of advantages and disadvantages. Modern Rheumatology Journal. 2011;(2):9-19 (in Russian)].
45. Huang H, Luo M, Liang H, et al. Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis. Pain Med. 2021;22(2):352-62. DOI:10.1093/pm/pnaa230
46. Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017;6(6):CD012095. DOI:10.1002/14651858.CD012095.pub2
47. Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013;15(1):R6. DOI:10.1186/ar4134

________________________________________________

1. Chaney S, Vergara R, Qiryaqoz Z, et al. The Involvement of Neutrophils in the Pathophysiology and Treatment of Osteoarthritis. Biomedicines. 2022;10(7):1604. DOI:10.3390/biomedicines10071604
2. Galushko EA, Bolshakova TY, Vinogradova IB, et al. Structure of rheumatic diseases among adult population of Russia according to data of an epidemiological study (preliminary results). Rheumatology Science and Practice. 2009;47(1):11-7 (in Russian). DOI:10.14412/1995-4484-2009-136
3. Berenbaum F. Deep phenotyping of osteoarthritis: a step forward. Ann Rheum Dis. 2019;78(1):3-5. DOI:10.1136/annrheumdis-2018-213864
4. Lila AM, Alekseeva LI, Telyshev KA. Current approaches to osteoarthritis phenotyping. Modern Rheumatology Journal. 2019;13(2):4-8 (in Russian).
5. Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018;320(24):2564-79. DOI:10.1001/jama.2018.19319
6. Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008;16(2):254-60. DOI:10.1016/j.joca.2007.06.011
7. Rovati LC, Girolami F, D'Amato M, Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016;45(Suppl. 4):S34-41. DOI:10.1016/j.semarthrit.2015.10.009
8. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254-66. DOI:10.1002/stem.1634
9. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol. 2013;9(10):584-94. DOI:10.1038/nrrheum.2013.109
10. Alekseeva LI. New ideas about the pathogenesis of osteoarthritis, the role of metabolic disorders. Obesity and Metabolism. 2019;16(2):75-82 (in Russian). DOI:10.14341/omet10274
11. Dagnino APA, Campos MM. Chronic Pain in the Elderly: Mechanisms and Perspectives. Front Hum Neurosci. 2022;16:736688. DOI:10.3389/fnhum.2022.736688
12. Leyland KM, Gates LS, Sanchez-Santos MT, et al; PCCOA Steering Committee. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res. 2021;33(3):529-45. DOI:10.1007/s40520-020-01762-2
13. Wang Y, Teichtahl AJ, Abram F, et al. Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Res Ther. 2018;20(1):250. DOI:10.1186/s13075-018-1751-4
14. Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797-807. DOI:10.1136/annrheumdis-2017-212662
15. Lim YZ, Wong J, Hussain SM, et al. Recommendations for weight management in osteoarthritis: A systematic review of clinical practice guidelines. Osteoarthr Cartil Open. 2022;4(4):100298. DOI:10.1016/j.ocarto.2022.100298
16. Stoll V, Jost JM, Jack A, et al. Non-steroidal Anti-inflammatory Drugs and Osteopathic Manipulative Treatment for Pain Management in Patients With Osteoarthritis: A Literature Review. Cureus. 2023;15(8):e44168. DOI:10.7759/cureus.44168
17. Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50. DOI:10.1016/j.semarthrit.2019.04.008
18. Gonartroz. Klinicheskie rekomendatsii Minzdrava RF. 2021 (in Russian).
19. Koksartroz. Klinicheskie rekomendatsii Minzdrava RF. 2021 (in Russian).
20. Uitterlinden EJ, Koevoet JL, Verkoelen CF, et al. Glucosamine increases hyaluronic acid production in human osteoarthritic synovium explants. BMC Musculoskelet Disord. 2008;9:120. DOI:10.1186/1471-2474-9-120
21. Veronese N, Demurtas J, Smith L, et al; on behalf on the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975927. DOI:10.1177/1759720X20975927
22. Alekseeva LI, Sharapova EP, Lila AM. Osteoarthritis of hand joints: prevalence, risk factors, phenotypes, diagnosis, treatment. Modern Rheumatology Journal. 2022;16(6):98-105 (in Russian). DOI:10.14412/1996-7012-2022-6-98-105
23. Tenti S, Giordano N, Mondanelli N, et al. A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone. Aging Clin Exp Res. 2020;32(6):1161-72. DOI:10.1007/s40520-019-01305-4
24. Reichelt A, Förster KK, Fischer M, et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. Arzneimittelforschung. 1994;44(1):75-80. PMID: 8135881
25. Honvo G, Reginster JY, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl. 1):65-99. DOI:10.1007/s40266-019-00662-z
26. Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P, et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis. 2016;245: 82-7. DOI:10.1016/j.atherosclerosis.2015.12.016
27. Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother. 2006;40(4): 694-8. DOI:10.1345/aph.1E658
28. Al-Kurdi ZI, Chowdhry BZ, Leharne SA, et al. Influence of glucosamine on the bioactivity of insulin delivered subcutaneously and in an oral nanodelivery system. Drug Des Devel Ther. 2015;9:6167-76. DOI:10.2147/DDDT.S91974
29. Cheng BR, Chen JQ, Zhang XW, et al. Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis. PLoS One. 2021;16(12):e0261239. DOI:10.1371/journal.pone.0261239
30. Nakata K, Hanai T, Take Y, et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2018;26(10):1263-73. DOI:10.1016/j.joca.2018.05.021
31. Taqi A, Gran S, Knaggs RD. Analgesic utilization in people with knee osteoarthritis: A population-based study using primary care data. Pain Pract. 2023;23(5):523-34. DOI:10.1111/papr.13212
32. Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(Suppl. 4):S22-7. DOI:10.1016/j.semarthrit.2015.11.009
33. Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-90.
DOI:10.1038/s41574-018-0059-4
34. Arendt Nielsen L, Schepman P, Hygge Blakeman K, et al. Prescription patterns and predictors of unmet pain relief in patients with difficult-to-treat osteoarthritis in the Nordics: analyses from the BISCUITS study. Scand J Pain. 2022;23(1):149-60. DOI:10.1515/sjpain-2021-0211
35. Swain S, Sarmanova A, Coupland C, et al. Comorbidities in Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken). 2020;72(7):991-1000. DOI:10.1002/acr.24008
36. Ryan A, Wallace E, O'Hara P, Smith SM. Multimorbidity and functional decline in community-dwelling adults: a systematic review. Health Qual Life Outcomes. 2015;13:168. DOI:10.1186/s12955-015-0355-9
37. Fortin M, Lapointe L, Hudon C, et al. Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes. 2004;2:51. DOI:10.1186/1477-7525-2-51
38. Karateev AE, Alekseeva LI, Tsurgan AV, Gontarenko NV. Therapy for acute/subacute musculoskeletal pain: results of the ATUSA (Analgesic Treatment Using a Systemic Algorithm) observational study. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(12):175-84 (in Russian). DOI:10.17116/terarkh20178912175-184
39. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12(5):570-6. DOI:10.1097/00001648-200109000-00018
40. Roberto G, Simonetti M, Piccinni C, et al. Risk of Acute Cerebrovascular and Cardiovascular Events Among Users of Acetaminophen or an Acetaminophen-Codeine Combination in a Cohort of Patients with Osteoarthritis: A Nested Case-Control Study. Pharmacotherapy. 2015;35(10):899-909. DOI:10.1002/phar.1646
41. Pontes C, Marsal JR, Elorza JM, et al. Analgesic Use and Risk for Acute Coronary Events in Patients With Osteoarthritis: A Population-based, Nested Case-control Study. Clin Ther. 2018;40(2):270-83. DOI:10.1016/j.clinthera.2017.12.011
42. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968-76. DOI:10.1001/archinternmed.2010.391
43. Karateev AE, Nasonov EL, Ivashkin VT, et al; Association of Rheumatologists of Russia, Russian Society for the Study of Pain, Russian Gastroenterology Association, Russian Scientific Medical Society of Therapists, Association of Traumatologists and Orthopedists of Russia, Russian Association of Palliative Medicine. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56(прил. 1):1-29 (in Russian). DOI:10.14412/1995-4484-2018-1-29
44. Karateev AE. Celecoxib, etoricoxib, meloxicam and nimesulide: comparison of advantages and disadvantages. Modern Rheumatology Journal. 2011;(2):9-19 (in Russian).
45. Huang H, Luo M, Liang H, et al. Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis. Pain Med. 2021;22(2):352-62. DOI:10.1093/pm/pnaa230
46. Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017;6(6):CD012095. DOI:10.1002/14651858.CD012095.pub2
47. Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013;15(1):R6. DOI:10.1186/ar4134